Synthesis and antiviral activity evaluation of new 4-thiazolidinones bearing an imidazo[2,1-b]thiazole moiety


Guzeldemirci N., Pehlivan E., NAESENS L.

MARMARA PHARMACEUTICAL JOURNAL, vol.22, no.2, pp.237-248, 2018 (ESCI) identifier identifier

  • Publication Type: Article / Article
  • Volume: 22 Issue: 2
  • Publication Date: 2018
  • Doi Number: 10.12991/mpj.2018.61
  • Journal Name: MARMARA PHARMACEUTICAL JOURNAL
  • Journal Indexes: Emerging Sources Citation Index (ESCI), Scopus, TR DİZİN (ULAKBİM)
  • Page Numbers: pp.237-248
  • Keywords: Imidazo[2,1-b]thiazoles, 4-thiazolidinones, antiviral activity, synthesis, VITRO ANTICANCER EVALUATION, ANTIOXIDANT ACTIVITY, ANTIMICROBIAL ACTIVITY, BIOLOGICAL EVALUATION, IN-SILICO, DERIVATIVES, AGENTS, ANTIFUNGAL, INHIBITORS, RECEPTOR
  • Istanbul University Affiliated: Yes

Abstract

A series of new 4-thiazolidinone derivatives were synthesized and evaluated against diverse DNA- and RNA-viruses in mammalian cell cultures. Some of the compounds were found to exhibit moderate antiviral activity. 3-Propyl-2-[((6-(4-chlorophenyl)imidazo[2,l-b]thiazol-3-yl)acetyl)hydrazono]-5-methyl-4-thiazolidinone 13, displayed modest yet consistent activity against three strains of influenza A virus, including the 2009 pandemic virus A/H1N1 Virginia/ ATCC3/2009 (cytotoxicity >100 mu M). Compounds 6 and 11 displayed activity against vesicular stomatitis virus in HeLa cells (antiviral EC50 values of 9 (cytotoxicity 100 mu M) and 2 mu M (cytotoxicity 20 mu M), respectively). Neither of the compounds was active against HIV.